MBL Japan Files For Approval Of Diagnostic Agent For EGFR Antibody Drug
This article was originally published in PharmAsia News
Executive Summary
Medical&Biological Laboratories Japan has, in collaboration with its subsidiary G&G Science, filed for the approval of a diagnostic agent for use in conjunction with anti-EGFR antibody drugs used in colorectal cancer treatment, the company announced on June 19.